Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 851 - 875 of 15158 in total

Sutilain

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000...
Approved
Withdrawn
Matched Description: … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. ... Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored …
Matched Categories: … Enzymes and Coenzymes …

Phenformin

A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Description: … A biguanide hypoglycemic agent with actions and uses similar to those of metformin. …
Matched Categories: … Alimentary Tract and Metabolism ... phenformin and sulfonylureas …

Lasofoxifene

Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as...
Approved
Investigational
Matched Description: … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment ... non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ... It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …

Tolazamide

A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Approved
Investigational
Matched Description: … A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Sulfameter

Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Approved
Matched Description: … Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections. …
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Mirvetuximab soravtansine

Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and ... the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Carbimazole

An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Factor XIII (human)

Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … and maintenance of hemostasis [A18581]. ... in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Nonacog beta pegol

Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Rilonacept

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Burosumab

Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …

Methoxy polyethylene glycol-epoetin beta

Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Butylscopolamine

Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic ... the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and …
Matched Categories: … Alimentary Tract and Metabolism ... Belladonna and Derivatives, Plain ... butylscopolamine and analgesics …

Hepatitis B Vaccine (Recombinant)

Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … the chronic complications such as chronic active hepatitis and cirrhosis. ... epidemiology vary widely among geographical areas and population subgroups. ... Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Bacterial and viral vaccines, combined ... haemophilus influenzae B and hepatitis B …

Migalastat

Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Chlorpropamide

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … increase the number and sensitivity of insulin receptors. ... Renal and hepatic dysfunction may increase the risk of hypoglycemia. ... Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Papaverine

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear,...
Approved
Investigational
Matched Description: … It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, ... mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives ... Genito Urinary System and Sex Hormones …

Polatuzumab vedotin

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Efalizumab

Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mirikizumab

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and ... [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ansuvimab

Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … to be superior, with improved patient survival and faster viral clearance rates. ... [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. ... evidenced by the previously approved INMAZEB™ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Fosdenopterin

Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites ... paraplegia, myoclonus, and opisthotonus. ... a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Fosaprepitant

Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Approved
Matched Iupac: … ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid …
Matched Description: … It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment …
Matched Categories: … Aprepitant and Prodrugs …

Chymopapain

Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It is an extracellular plant cysteine proteinase similar to papain in specificity. Chymopapain was developed by Chart Medcl and FDA approved...
Approved
Withdrawn
Matched Description: … [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. …
Matched Categories: … Enzymes and Coenzymes …

Certoparin

Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Approved
Investigational
Matched Categories: … Heparin and similars …
Displaying drugs 851 - 875 of 15158 in total